Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA. Chavan SS, et al. Among authors: steward d. Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12. Blood Cancer J. 2017. PMID: 28234347 Free PMC article.
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Jethava Y, et al. Among authors: steward d. Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64. Blood Cancer J. 2016. PMID: 27471869 Free PMC article. Clinical Trial.
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Davies FE, et al. Among authors: steward dm. Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22. Haematologica. 2018. PMID: 29567784 Free PMC article.
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B. Usmani SZ, et al. Among authors: steward d. Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25. Leukemia. 2014. PMID: 25151956 Clinical Trial. No abstract available.
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Jethava Y, et al. Among authors: steward d. Blood Cancer J. 2016 Sep 16;6(9):e471. doi: 10.1038/bcj.2016.85. Blood Cancer J. 2016. PMID: 27635734 Free PMC article. No abstract available.
Midline Catheter Use in the Neonatal Intensive Care Unit.
Sykes S, Ulloa J, Steward D. Sykes S, et al. Among authors: steward d. Crit Care Nurs Clin North Am. 2024 Mar;36(1):111-118. doi: 10.1016/j.cnc.2023.09.004. Epub 2023 Oct 23. Crit Care Nurs Clin North Am. 2024. PMID: 38296369 Review.
335 results